Core Viewpoint - Zhonghui Biotech-B (02627) reported a significant revenue increase of 919.25% year-on-year, reaching RMB 71.123 million for the six months ending June 30, 2025, indicating strong growth in the vaccine sector [1] Company Overview - Established in 2015, the company is a China-based vaccine manufacturer focused on the research, development, manufacturing, and commercialization of innovative vaccines and traditional vaccines using new technologies [1] - The company has two core products: a quadrivalent influenza virus subunit vaccine and an investigational freeze-dried human rabies vaccine, along with 11 other investigational vaccines targeting various diseases with high vaccination demand [1] Research and Development - The company has established three comprehensive vaccine development support platforms: a gene engineering and protein expression and purification platform, an mRNA vaccine research platform, and an adjuvant development and production platform, enhancing its ability to discover and develop various new vaccines [1] - The company has also developed proprietary technology platforms, including large-scale amplification, polysaccharide conjugation technology, and microbiology and immunology research platforms, to further boost its R&D capabilities [1] - As of June 30, 2025, the company successfully obtained IND approvals from the National Medical Products Administration for nine investigational vaccines [1]
中慧生物-B(02627)发布中期业绩 收入7112.3万元 同比大涨919.25%